Concepts (192)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Malate Dehydrogenase | 1 | 2024 | 8 | 0.880 |
Why?
|
| Cytosol | 1 | 2024 | 97 | 0.860 |
Why?
|
| Artificial Intelligence | 1 | 2026 | 112 | 0.850 |
Why?
|
| Protein Binding | 1 | 2024 | 1082 | 0.670 |
Why?
|
| Biomedical Research | 1 | 2021 | 502 | 0.460 |
Why?
|
| Minority Groups | 1 | 2021 | 690 | 0.460 |
Why?
|
| Pterocarpans | 6 | 2024 | 25 | 0.430 |
Why?
|
| Estrogens | 6 | 2012 | 203 | 0.390 |
Why?
|
| Sesquiterpenes | 4 | 2025 | 38 | 0.380 |
Why?
|
| Estrogen Receptor alpha | 10 | 2025 | 121 | 0.370 |
Why?
|
| Receptors, Estrogen | 6 | 2025 | 183 | 0.370 |
Why?
|
| Isoflavones | 3 | 2025 | 132 | 0.340 |
Why?
|
| Phytoestrogens | 4 | 2024 | 39 | 0.330 |
Why?
|
| Selective Estrogen Receptor Modulators | 2 | 2016 | 31 | 0.310 |
Why?
|
| Pyridines | 2 | 2022 | 139 | 0.250 |
Why?
|
| Judgment | 1 | 2026 | 20 | 0.240 |
Why?
|
| Calibration | 1 | 2026 | 63 | 0.240 |
Why?
|
| Pueraria | 1 | 2025 | 4 | 0.230 |
Why?
|
| Humans | 27 | 2026 | 43102 | 0.230 |
Why?
|
| Cell Proliferation | 9 | 2025 | 1455 | 0.210 |
Why?
|
| Fundulidae | 2 | 2016 | 7 | 0.210 |
Why?
|
| Breast Neoplasms | 8 | 2017 | 1723 | 0.210 |
Why?
|
| Cell Line, Tumor | 12 | 2024 | 2676 | 0.190 |
Why?
|
| Longitudinal Studies | 1 | 2026 | 1063 | 0.190 |
Why?
|
| DDT | 2 | 2012 | 15 | 0.180 |
Why?
|
| Butyrates | 1 | 2002 | 34 | 0.180 |
Why?
|
| Benzodiazepines | 1 | 2022 | 21 | 0.180 |
Why?
|
| Communication Disorders | 1 | 2022 | 8 | 0.180 |
Why?
|
| Estrogen Antagonists | 3 | 2010 | 30 | 0.180 |
Why?
|
| Endocrine Disruptors | 2 | 2012 | 44 | 0.180 |
Why?
|
| Plant Extracts | 4 | 2024 | 302 | 0.170 |
Why?
|
| Triazoles | 1 | 2022 | 102 | 0.170 |
Why?
|
| Estradiol | 3 | 2012 | 268 | 0.170 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 2 | 2011 | 31 | 0.170 |
Why?
|
| Maryland | 1 | 2021 | 66 | 0.170 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 1019 | 0.160 |
Why?
|
| Research Personnel | 1 | 2021 | 206 | 0.150 |
Why?
|
| Response Elements | 4 | 2015 | 55 | 0.140 |
Why?
|
| Receptors, Aryl Hydrocarbon | 2 | 2015 | 49 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2015 | 968 | 0.130 |
Why?
|
| Animals | 10 | 2024 | 16992 | 0.130 |
Why?
|
| Gene Expression Regulation | 3 | 2012 | 1070 | 0.130 |
Why?
|
| Sterols | 1 | 2016 | 24 | 0.130 |
Why?
|
| Boronic Acids | 1 | 2016 | 21 | 0.120 |
Why?
|
| RNA, Small Interfering | 2 | 2017 | 436 | 0.120 |
Why?
|
| Aptamers, Nucleotide | 1 | 2017 | 51 | 0.120 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2015 | 28 | 0.120 |
Why?
|
| Isoenzymes | 3 | 2011 | 168 | 0.120 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2015 | 11 | 0.110 |
Why?
|
| Estrogen Receptor beta | 3 | 2010 | 39 | 0.110 |
Why?
|
| Signal Transduction | 6 | 2016 | 2157 | 0.110 |
Why?
|
| Coumarins | 1 | 2015 | 45 | 0.110 |
Why?
|
| Phenanthrenes | 1 | 2014 | 16 | 0.110 |
Why?
|
| Down-Regulation | 2 | 2016 | 456 | 0.110 |
Why?
|
| Regional Health Planning | 1 | 2013 | 14 | 0.100 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2015 | 134 | 0.100 |
Why?
|
| Minority Health | 1 | 2013 | 95 | 0.100 |
Why?
|
| Sapogenins | 1 | 2012 | 3 | 0.100 |
Why?
|
| Alternative Splicing | 1 | 2012 | 94 | 0.090 |
Why?
|
| Stereoisomerism | 4 | 2016 | 169 | 0.090 |
Why?
|
| Environmental Pollutants | 1 | 2014 | 201 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2012 | 137 | 0.090 |
Why?
|
| Receptors, Androgen | 1 | 2012 | 144 | 0.090 |
Why?
|
| Biomimetics | 1 | 2011 | 15 | 0.090 |
Why?
|
| Nanoparticles | 1 | 2017 | 460 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2016 | 307 | 0.080 |
Why?
|
| Phenols | 1 | 2012 | 107 | 0.080 |
Why?
|
| Adamantane | 1 | 2010 | 10 | 0.080 |
Why?
|
| Thiazoles | 1 | 2011 | 76 | 0.080 |
Why?
|
| Phaseolus | 1 | 2010 | 20 | 0.080 |
Why?
|
| Transcription, Genetic | 5 | 2012 | 592 | 0.080 |
Why?
|
| Molecular Structure | 3 | 2025 | 570 | 0.080 |
Why?
|
| Cell Survival | 5 | 2011 | 945 | 0.080 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2009 | 19 | 0.080 |
Why?
|
| Terpenes | 1 | 2009 | 30 | 0.080 |
Why?
|
| MAP Kinase Kinase 5 | 1 | 2008 | 4 | 0.070 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2009 | 64 | 0.070 |
Why?
|
| Anticarcinogenic Agents | 1 | 2009 | 77 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2008 | 8 | 0.070 |
Why?
|
| Flavonols | 1 | 2008 | 19 | 0.070 |
Why?
|
| Fermentation | 1 | 2008 | 39 | 0.070 |
Why?
|
| Female | 11 | 2022 | 24698 | 0.070 |
Why?
|
| Mesoderm | 1 | 2008 | 73 | 0.070 |
Why?
|
| Structure-Activity Relationship | 3 | 2016 | 506 | 0.070 |
Why?
|
| Epithelium | 1 | 2008 | 78 | 0.070 |
Why?
|
| Healthcare Disparities | 1 | 2013 | 590 | 0.070 |
Why?
|
| Health Services Accessibility | 1 | 2013 | 706 | 0.070 |
Why?
|
| Health Status Disparities | 1 | 2013 | 719 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 384 | 0.060 |
Why?
|
| Bufanolides | 1 | 2006 | 2 | 0.060 |
Why?
|
| Proteomics | 1 | 2008 | 378 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2012 | 518 | 0.060 |
Why?
|
| Pre-Eclampsia | 1 | 2006 | 67 | 0.060 |
Why?
|
| Aspergillus | 1 | 2024 | 14 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 652 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2003 | 508 | 0.050 |
Why?
|
| Blotting, Western | 3 | 2011 | 883 | 0.050 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 2003 | 20 | 0.050 |
Why?
|
| Fabaceae | 1 | 2003 | 30 | 0.050 |
Why?
|
| Tamoxifen | 2 | 2016 | 69 | 0.050 |
Why?
|
| Neoplasms | 1 | 2013 | 1377 | 0.050 |
Why?
|
| Luciferases | 2 | 2015 | 71 | 0.050 |
Why?
|
| Molecular Mimicry | 1 | 2002 | 16 | 0.050 |
Why?
|
| Models, Chemical | 2 | 2015 | 204 | 0.050 |
Why?
|
| Biotransformation | 1 | 2002 | 69 | 0.050 |
Why?
|
| Genes, Reporter | 2 | 2015 | 148 | 0.050 |
Why?
|
| Models, Molecular | 3 | 2010 | 876 | 0.050 |
Why?
|
| Ovariectomy | 1 | 2002 | 127 | 0.040 |
Why?
|
| Cells, Cultured | 3 | 2010 | 1621 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2022 | 317 | 0.040 |
Why?
|
| Cell Line | 3 | 2010 | 1410 | 0.040 |
Why?
|
| Phosphorylation | 2 | 2015 | 986 | 0.040 |
Why?
|
| Transcriptional Activation | 2 | 2010 | 173 | 0.040 |
Why?
|
| Mice | 4 | 2012 | 6644 | 0.040 |
Why?
|
| Hypertension | 1 | 2006 | 835 | 0.040 |
Why?
|
| Mice, Nude | 2 | 2010 | 408 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2010 | 347 | 0.040 |
Why?
|
| Rats | 2 | 2006 | 3735 | 0.040 |
Why?
|
| Gene Expression Profiling | 2 | 2015 | 704 | 0.030 |
Why?
|
| Gene Expression | 2 | 2010 | 701 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2022 | 1604 | 0.030 |
Why?
|
| Excipients | 1 | 2017 | 25 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2017 | 154 | 0.030 |
Why?
|
| Species Specificity | 1 | 2016 | 286 | 0.030 |
Why?
|
| Biological Availability | 1 | 2016 | 116 | 0.030 |
Why?
|
| Liposomes | 1 | 2017 | 132 | 0.030 |
Why?
|
| Fluorocarbons | 1 | 2016 | 42 | 0.030 |
Why?
|
| Particle Size | 1 | 2017 | 272 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 260 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2011 | 465 | 0.030 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2015 | 98 | 0.030 |
Why?
|
| Base Sequence | 1 | 2016 | 983 | 0.030 |
Why?
|
| Genetic Engineering | 1 | 2014 | 37 | 0.030 |
Why?
|
| Toxicity Tests | 1 | 2014 | 44 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2017 | 277 | 0.030 |
Why?
|
| Methylation | 1 | 2014 | 119 | 0.030 |
Why?
|
| Biological Assay | 1 | 2014 | 63 | 0.030 |
Why?
|
| Ligands | 1 | 2015 | 388 | 0.030 |
Why?
|
| Southeastern United States | 1 | 2013 | 64 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2016 | 1542 | 0.030 |
Why?
|
| Drug Design | 1 | 2015 | 186 | 0.030 |
Why?
|
| Kinetics | 1 | 2015 | 695 | 0.030 |
Why?
|
| Interinstitutional Relations | 1 | 2013 | 51 | 0.030 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2014 | 199 | 0.020 |
Why?
|
| Community Networks | 1 | 2013 | 107 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 299 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2013 | 178 | 0.020 |
Why?
|
| Prostatic Neoplasms | 2 | 2012 | 1092 | 0.020 |
Why?
|
| Male | 3 | 2022 | 23409 | 0.020 |
Why?
|
| Insecticides | 1 | 2012 | 54 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2012 | 116 | 0.020 |
Why?
|
| Benzhydryl Compounds | 1 | 2012 | 50 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 1869 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 455 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2011 | 157 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2010 | 92 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2011 | 301 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2011 | 280 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2010 | 219 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2009 | 129 | 0.020 |
Why?
|
| Fruit | 1 | 2010 | 178 | 0.020 |
Why?
|
| Puerto Rico | 1 | 2013 | 1413 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2010 | 575 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2010 | 416 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2008 | 32 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2008 | 109 | 0.020 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2008 | 78 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2011 | 408 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2008 | 196 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 127 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 934 | 0.020 |
Why?
|
| Binding Sites | 1 | 2009 | 671 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2008 | 182 | 0.020 |
Why?
|
| Glucose | 1 | 2009 | 244 | 0.020 |
Why?
|
| Ovarian Neoplasms | 1 | 2011 | 415 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2008 | 241 | 0.020 |
Why?
|
| Ouabain | 1 | 2006 | 15 | 0.020 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2006 | 28 | 0.010 |
Why?
|
| Phenotype | 1 | 2008 | 780 | 0.010 |
Why?
|
| Models, Biological | 1 | 2008 | 712 | 0.010 |
Why?
|
| Adult | 1 | 2022 | 13872 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2008 | 1271 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2006 | 458 | 0.010 |
Why?
|
| Methanol | 1 | 2003 | 22 | 0.010 |
Why?
|
| Plant Preparations | 1 | 2003 | 24 | 0.010 |
Why?
|
| Embryo, Mammalian | 1 | 2003 | 157 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 311 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2006 | 666 | 0.010 |
Why?
|
| Transfection | 1 | 2003 | 532 | 0.010 |
Why?
|
| Kidney | 1 | 2003 | 372 | 0.010 |
Why?
|
| Pregnancy | 1 | 2006 | 1772 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2006 | 1596 | 0.010 |
Why?
|